Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 17/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.30 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.30 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200414 | 0.92 | S1PR1 (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL2111707 | 0.83 | SSTR4 (0.41) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Trifluoroacetic Acid SCHEMBL2111767 | 0.82 | SSTR4 (0.35) | SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2111709 | 0.82 | KMO (0.43) | SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2111976 | 0.81 | SSTR4 (0.37) | SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2111688 | 0.79 | SSTR4 (0.38) | SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2110957 | 0.79 | SSTR4 (0.36) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| Trifluoroacetic Acid SCHEMBL2111852 | 0.78 | SSTR4 (0.39) | SSTR4KDM1A | |
| Trifluoroacetic Acid SCHEMBL2110684 | 0.78 | ASIC3 (0.36) | SSTR4 | |
| Trifluoroacetic Acid SCHEMBL2110708 | 0.77 | SSTR4 (0.37) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9079907-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SHIRAI JUNYA (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8158617-B2 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165312-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | SSTR4 87/4885KDM1A 2568/4885SSTR1 89/4885 |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | SSTR4 87/4885KDM1A 2568/4885SSTR1 89/4885 |
| US-20150238506-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | HTR2C, HTR3C, HTR3B | SSTR4 87/4885KDM1A 2568/4885SSTR1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.